We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 15, 2020

Low-Dose TKIs Before Treatment Discontinuation Do Not Impair Treatment-Free Remission in CLL Patients

Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cancer
Low-Dose Tyrosine Kinase Inhibitors Before Treatment Discontinuation Do Not Impair Treatment-Free Remission in Chronic Myeloid Leukemia Patients: Results of a Retrospective Study
Cancer 2020 May 27;[EPub Ahead of Print], E Cayssials, J Torregrosa-Diaz, P Gallego-Hernanz, F Tartarin, T Systchenko, N Maillard, D Desmier, A Machet, E Fleck, A Corby, C Motard, G Denis, A Herbelin, JM Gombert, L Roy, S Ragot, X Leleu, F Guilhot, JC Chomel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading